Medical Marijuana, Inc. Subsidiary Kannaway® Enters CBN Market; Expands Cannabinoid PortfolioPosted by On

/EIN News/ — SAN DIEGO, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) — via NewMediaWireMedical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has officially entered the U.S. cannabinol (CBN) market with the release of two new CBN isolate products. 

Not to be confused with cannabidiol (CBD), which has gained significant popularity over the past few years, CBN is another non-psychoactive cannabinoid found in the cannabis plant. Like the Company’s full-spectrum CBD products, Kannaway®’s CBN products are derived from all-natural hemp.

“We’re very excited to become one of the first major hemp-derived product producers to offer CBN,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is being…

Original Author Link click here to read complete story..

News

CannabinoidCBNEntersexpandsKannawaymarijuanamarketmedicalPortfolioSubsidiary

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.